Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study-Reference-Cited by-同舟云学术

Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study

Published:2023-05-20 Issue:10 Volume:44 Page:3629-3635
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Papathanasiou Athanasios,Hibbert Aimee^ORCID,Tallantyre Emma,Harding Katharine,Selvam Adithya Panneer,Morgan Matthew,Quainton Charlotte,Talaei Maryam,Arun Tarunya,Ingram Gillian,Law Graham R.,Evangelou Nikos

Funder

Roche Products

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-023-06838-1.pdf

Reference26 articles.

1. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73(20):1616–1623. https://doi.org/10.1212/WNL.0b013e3181c1e44f

2. Nazareth TA, Rava AR, Polyakov JL et al (2018) Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. Mult Scler Relat Disord 26:219–234. https://doi.org/10.1016/j.msard.2018.09.002

3. Tremlett H, Zhao Y, Joseph J, Devonshire V, the UBCMS Clinic Neurologists. (2008) Relapses in multiple sclerosis are age-and time-dependent. J Neurol Neurosurg Psychiatry 79:1368–1375. https://doi.org/10.1136/jnnp.2008.145805

4. Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T (2012) Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler 18(9):1290–1296. https://doi.org/10.1177/1352458511435715

5. Lavery AM, Verhey LH, Waldman AT (2014) Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int 2014:262350. https://doi.org/10.1155/2014/262350

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. χ-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis;Neurology;2024-09-24

2. Safety and effectiveness of disease-modifying therapies after switching from natalizumab;Multiple Sclerosis Journal;2024-07

3. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop);European Journal of Neurology;2024-03-28

4. The effect of COVID-19 on Multiple Sclerosis relapse: A systematic review and meta-analysis;Multiple Sclerosis and Related Disorders;2024-01